Penumbra Introduces POD® Packing Coil for the Embolization of Peripheral Vessels and Aneurysms

Adds to Indigo® Mechanical Thrombectomy
System, POD and Ruby
® Embolization Coils in
Growing Peripheral Vascular Business

ALAMEDA, Calif. –
., a global interventional therapies company, today announced the
U.S. launch of its new POD® Packing Coil, designed to be used
as a complementary device with Penumbra’s Ruby® and POD
(Penumbra Occlusion Device) embolization products. This latest launch
adds to the company’s rapidly expanding peripheral vascular product
portfolio. Nearly 900,000 Americans each year suffer from peripheral
vascular conditions involving acute clots or aneurysms that occur
outside the brain or heart, and this represents a large and growing
patient population.

This Smart News Release features multimedia. View the full release here:

Penumbra has developed a suite of thrombectomy and embolization products
for use in a range of peripheral vascular conditions, and these products
are driving significant growth:

  • Penumbra’s embolization platform includes Ruby and POD and the new POD
    Packing Coil, which is uniquely designed to pack very densely behind
    Ruby and POD to occlude arteries and veins throughout the peripheral
    vasculature, including aneurysms.
  • Penumbra’s next-generation Indigo® System is a continuous
    aspiration thrombectomy device designed to remove fresh, soft emboli
    and thrombi from the peripheral arteries and veins. The Indigo System
    includes four catheter sizes (CAT 3, 5, 6 and 8). The aspiration lumen
    is paired with a proprietary continuous vacuum aspiration pump to
    evacuate clot effectively and efficiently.

“With the Indigo System and POD, Penumbra has recently introduced
products that have had significant impact on the treatment of vascular
disease. Indigo represents a significant advancement in the treatment of
thrombotic and embolic disease, which until now has had limited
treatment options,” said Corey Teigen, MD, at Sanford Health in Fargo,
ND, who uses Penumbra’s peripheral vascular products. “With the Indigo
System, physicians now have the ability to remove limb- and
life-threatening clots quickly and efficiently. Likewise the POD, Ruby
and now the POD Packing Coil optimize embolization procedures by
decreasing procedure time while providing increased control.”

“Our embolization platform and the Indigo System are examples of our
commitment to innovating new technologies for challenging vascular
conditions for which there are significant unmet clinical needs,” said
Adam Elsesser, Chairman and CEO of Penumbra. “We are intent on changing
treatment paradigms to improve clinical outcomes across two large and
growing markets: neuro and peripheral vascular.”

About Peripheral Vascular Disease

Peripheral vascular disease includes blood clots or aneurysms that
affect the vessels of the upper and lower extremities and all other
parts of the body except the brain and heart. There are nearly 900,000
people in the U.S. annually who suffer from acute clots or aneurysms in
the body that may be treated by thrombectomy or embolization procedures.

Penumbra’s peripheral vascular product portfolio currently focuses on
thrombectomy and embolization therapies:

  • Peripheral thrombectomy involves the removal of blood clots. There are
    an estimated 850,000 people in the U.S. who develop such conditions,
    and approximately 150,000 are treated per year with existing
    procedures including catheter-directed thrombolysis (clot-busting
  • Peripheral embolization involves obstructing blood flow to target
    vessels, aneurysms and vascular anomalies, and assisting with the
    treatment of oncological disease. There are approximately 50,000
    patients treated each year in the U.S. for such conditions.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global
interventional therapies company that designs, develops, manufactures
and markets innovative medical devices. The company has a broad
portfolio of products that address challenging medical conditions and
significant clinical needs across two major markets, neuro and
peripheral vascular. Penumbra sells its products to hospitals primarily
through its direct sales organization in the U.S., most of Europe,
Canada and Australia, and through distributors in select international
markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc.

Forward-Looking Statements

Except for historical information, certain statements in this press
release are forward-looking in nature and are subject to risks,
uncertainties and assumptions about us. Our business and operations are
subject to a variety of risks and uncertainties and, consequently,
actual results may differ materially from those projected by any
forward-looking statements. Factors that could cause actual results to
differ from those projected include, but are not limited to: failure to
sustain or grow profitability or generate positive cash flows; failure
to effectively introduce and market new products; delays in product
introductions; significant competition; inability to further penetrate
our current customer base, expand our user base and increase the
frequency of use of our products by our customers; inability to achieve
or maintain satisfactory pricing and margins; manufacturing
difficulties; permanent write-downs or write-offs of our inventory;
product defects or failures; unfavorable outcomes in clinical trials;
inability to maintain our culture as we grow; fluctuations in foreign
currency exchange rates; and potential adverse regulatory actions. These
risks and uncertainties, as well as others, are discussed in greater
detail in our filings with the Securities and Exchange Commission,
including our prospectus dated September 17, 2015. There may be
additional risks of which we are not presently aware or that we
currently believe are immaterial which could have an adverse impact on
our business. Any forward-looking statements are based on our current
expectations, estimates and assumptions regarding future events and are
applicable only as of the dates of such statements. We make no
commitment to revise or update any forward-looking statements in order
to reflect events or circumstances that may change.

Source: Penumbra, Inc.

Merryman Communications
Betsy Merryman, 310-560-8176
[email protected]


Contact us to learn more about our products and company